IFF reports solid FY 25 operating EBITDA of USD 2.1B despite sales decline
The results were fueled by volumes, productivity, and selective pricing.
USA – International Flavours & Fragrances Inc. (IFF) has reported its fourth quarter and full-year 2025 financial results, showcasing resilience amid economic pressures and portfolio reshaping efforts.
Erik Fyrwald, CEO of IFF, stated, “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment.”
“It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.”
For the full year 2025, consolidated net sales totalled USD 10.89 billion, down 5% as reported but up 2% on a comparable currency-neutral basis.
GAAP loss before taxes was USD 412 million, yet adjusted operating EBITDA hit USD 2.086 billion, a 7% comparable currency-neutral gain with a 19.2% margin, while adjusted EPS excluding amortization reached USD 4.20 per diluted share.
Operating cash flow generated USD 850 million, yielding USD 256 million in free cash flow after capital expenditures, with net leverage at 2.6x net debt to credit-adjusted EBITDA, supporting deleveraging goals amid ongoing transformations.
For the full year, the Scent segment reported USD 2.24 billion in sales, while the Health & Biosciences segment reported basic sales of USD 2.28 billion.
Q4 financial performance
In the fourth quarter, the company reported net sales of USD 2.59 billion, reflecting a 7% year-over-year decline due to adverse currency effects and divestment impacts, though comparable currency-neutral sales rose 1%—buoyed by mid-single-digit advances in Health & Biosciences and Scent, against a robust prior-year benchmark.
Income before taxes reached USD 22 million on a GAAP basis, while adjusted operating EBITDA climbed to USD 437 million with a 16.9% margin, marking a comparable 17% currency-neutral increase driven by advantageous pricing, cost efficiencies, and disciplined operations.
Adjusted EPS excluding amortization stood at USD 0.80, underscoring underlying strength after adjustments for one-off items, including restructuring, integration costs, and intangible amortization.
Segment-wise, Taste delivered resilient performance with full-year organic growth; Scent recorded Q4 sales of USD 610 million and USD 106 million adjusted operating EBITDA (17.4% margin, up 1% comparably); Health & Biosciences posted Q4 sales of USD 589 million and USD 155 million adjusted EBITDA (26.3% margin, up 20% currency-neutral via volumes and efficiencies).
For 2026, IFF anticipates 4-6% organic sales growth, 100-150 basis point adjusted EBITDA margin expansion, and adjusted EPS of USD 5.40-USD 5.70, propelled by innovation, supply chain refinements, and premium market penetration, while cautioning on risks like geopolitical strains, input cost swings, and regulatory hurdles as outlined in SEC documents.
Non-GAAP figures, reconciled in the release, exclude amortization, realignments, and strategic costs to highlight core operations without supplanting GAAP metrics.
Looking to 2026, IFF forecasts organic sales growth of 4-6%, with adjusted EBITDA margins expanding another 100-150 basis points and adjusted EPS of USD 5.40-USD 5.70, propelled by innovation pipelines, supply chain optimizations, and market share gains in premium categories.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
